OBJECTIVE: We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors that significantly influence the remission. METHODS: Forty-two patients with GH-secreting pituitary adenoma underwent transsphenoidal surgery (TSS) between 1995 and 2007. The patient group included 23 women and 19 men, with a mean age of 40.2 (range 13-61) years, and a mean follow-up duration of 49.4 (range 3-178) months after the operation. For comparable radiological criteria, we classified parasellar growth into five grades according to the Knosp classification. We analyzed the surgical results of the patients according to the most recent stringent criteria for cure. RESULTS: The overall rate of endocrinological remission in the group of 42 patients after primary TSS was 64% (26 of 42). The remission rate was 67% (8 of 12) for microadenoma and 60% (18 of 30) for macroadenoma. The remission rate was 30% (3 of 10) for the group with cavernous sinus invasion and 72% (23 of 32) for the group with intact cavernous sinus. Cavernous sinus invasion in Knosp grade III and IV was significantly correlated with the remission rate. There was a significant relationship between preoperative mean GH concentration and early postoperative outcome, with most patients in remission having a lower preoperative GH concentration. CONCLUSION: TSS is thought to be an effective primary treatment for GH-secreting pituitary adenomas according to the most recent criteria of cure. Because the remission rate in cases with cavernous sinus invasion is very low, early detection of the tumor before it extends into the cavernous sinus and a long-term endocrinological and radiological follow-up are necessary in order to improve the remission rate of acromegaly.
OBJECTIVE: We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors that significantly influence the remission. METHODS: Forty-two patients with GH-secreting pituitary adenoma underwent transsphenoidal surgery (TSS) between 1995 and 2007. The patient group included 23 women and 19 men, with a mean age of 40.2 (range 13-61) years, and a mean follow-up duration of 49.4 (range 3-178) months after the operation. For comparable radiological criteria, we classified parasellar growth into five grades according to the Knosp classification. We analyzed the surgical results of the patients according to the most recent stringent criteria for cure. RESULTS: The overall rate of endocrinological remission in the group of 42 patients after primary TSS was 64% (26 of 42). The remission rate was 67% (8 of 12) for microadenoma and 60% (18 of 30) for macroadenoma. The remission rate was 30% (3 of 10) for the group with cavernous sinus invasion and 72% (23 of 32) for the group with intact cavernous sinus. Cavernous sinus invasion in Knosp grade III and IV was significantly correlated with the remission rate. There was a significant relationship between preoperative mean GH concentration and early postoperative outcome, with most patients in remission having a lower preoperative GH concentration. CONCLUSION: TSS is thought to be an effective primary treatment for GH-secreting pituitary adenomas according to the most recent criteria of cure. Because the remission rate in cases with cavernous sinus invasion is very low, early detection of the tumor before it extends into the cavernous sinus and a long-term endocrinological and radiological follow-up are necessary in order to improve the remission rate of acromegaly.
Authors: A Giustina; A Barkan; F F Casanueva; F Cavagnini; L Frohman; K Ho; J Veldhuis; J Wass; K Von Werder; S Melmed Journal: J Clin Endocrinol Metab Date: 2000-02 Impact factor: 5.958
Authors: Marek Bolanowski; Katarzyna Zatonska; Marcin Kaluzny; Grzegorz Zielinski; Grazyna Bednarek-Tupikowska; Anna Bohdanowicz-Pawlak; Jacek Daroszewski; Jadwiga Szymczak; Jan Krzysztof Podgorski Journal: Neuro Endocrinol Lett Date: 2006-12 Impact factor: 0.765
Authors: B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: Hussein Fathalla; Michael D Cusimano; Antonio Di Ieva; John Lee; Omar Alsharif; Jeannette Goguen; Stanley Zhang; Harley Smyth Journal: Neurosurg Rev Date: 2015-02-10 Impact factor: 3.042
Authors: Samuel S Shin; Matthew J Tormenti; Alessandro Paluzzi; William E Rothfus; Yue-Fang Chang; Hanady Zainah; Juan C Fernandez-Miranda; Carl H Snyderman; Sue M Challinor; Paul A Gardner Journal: Pituitary Date: 2013-12 Impact factor: 4.107
Authors: Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku Journal: Endocrine Date: 2019-11-01 Impact factor: 3.633
Authors: Christa C van Bunderen; Nadège C van Varsseveld; Johannes C Baayen; Wouter R van Furth; Esther Sanchez Aliaga; Marieke J Hazewinkel; Charles B L M Majoie; Nicole J M Freling; Paul Lips; Eric Fliers; Peter H Bisschop; Madeleine L Drent Journal: Pituitary Date: 2013-06 Impact factor: 4.107